贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性  

Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer

作　　者：周婷 徐少华 梅林[1] Zhou Ting;Xu Shaohua;Mei Lin(Department of Oncology,People's Liberation Army Navy Anqing Hospital,Anqing 246000,China)

机构地区：[1]中国人民解放军海军安庆医院肿瘤内科,安庆246000

出　　处：《国际肿瘤学杂志》2023年第3期144-149,共6页Journal of International Oncology

摘　　要：目的探讨晚期乳腺癌应用贝伐珠单抗联合卡培他滨治疗的有效性及安全性。方法选择2019年8月至2021年5月于中国人民解放军海军安庆医院肿瘤中心收治确诊的76例晚期乳腺癌患者,根据治疗方案不同,将患者分为对照组(采用单药卡培他滨治疗)和试验组(采用贝伐珠单抗联合卡培他滨治疗),每组38例。治疗4个周期后对比两组患者的临床疗效、无进展生存期(PFS)、总生存期(OS)和不良反应,比较治疗前后患者血管内皮生长因子(VEGF)-121、VEGF-145、VEGF-165水平、生命质量。结果试验组的客观缓解率[57.89%(22/38)]虽高于对照组[42.11%(16/38)],但差异无统计学意义(χ^(2)=1.89,P=0.169);试验组的疾病控制率[81.58%(31/38)]优于对照组[55.26%(21/38)],差异有统计学意义(χ^(2)=6.09,P=0.014)。试验组患者中位PFS(6.3个月)长于对照组(4.2个月),差异有统计学意义(χ^(2)=0.48,P=0.003);试验组患者中位OS(14.8个月)与对照组(13.2个月)比较,差异无统计学意义(χ^(2)=0.15,P=0.704)。治疗后试验组患者血清VEGF-121[(201.25±18.37)ng/L比(276.83±20.26)ng/L]、VEGF-145[(102.24±12.16)ng/L比(170.39±15.28)ng/L]、VEGF-165[(135.08±14.32)ng/L比(210.53±16.09)ng/L]水平比对照组低,差异均有统计学意义(t=17.03,P<0.001;t=21.51,P<0.001;t=21.59,P<0.001)。治疗后试验组健康调查简表(SF-36)生理功能[(80.18±13.96)分比(71.72±16.12)分]、生理职能[(67.19±30.62)分比(53.12±9.86)分]、躯体疼痛[(70.01±17.97)分比(61.06±17.57)分]、总体健康[(68.67±18.92)分比(57.96±20.97)分]、活力[(78.39±19.37)分比(68.26±18.52)分]、社会功能[(82.24±19.73)分比(70.92±20.31)分]、情感职能[(73.81±28.86)分比(60.23±29.19)分]、精神健康[(76.19±12.82)分比(70.31±12.54)分]评分均高于对照组,差异均有统计学意义(t=2.45,P=0.017;t=2.03,P=0.046;t=2.19,P=0.031;t=2.34,P=0.022;t=2.33,P=0.023;t=2.46,P=0.016;t=2.04,P=0.045;t=2.02,P=0.047)。试验组患者不良反应发生率[18Objective To investigate the efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer.Methods Seventy-six patients with advanced breast cancer who were diagnosed in the Cancer Center of the People's Liberation Army Navy Anqing Hospital from August 2019 to May 2021 were selected.According to different treatment schemes,the patients were divided into the control group(using single drug capecitabine)and the test group(using bevacizumab combined with capecitabine),with 38 cases in each group.After 4 cycles of treatment,the clinical efficacy,progression-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups,and the levels of vascular endothelial growth factor(VEGF)-121,VEGF-145,VEGF-165 and quality of life before and after treatment were compared.Results The objective remission rate of the test group[57.89%(22/38)]was higher than that of the control group[42.11%(16/38)],but there was no statistically significant difference(χ^(2)=1.89,P=0.169);The disease control rate of the test group[81.58%(31/38)]was better than that of the control group[55.26%(21/38)],there was a statistically significant difference(χ^(2)=6.09,P=0.014).The median PFS of patients in the test group(6.3 months)was longer than that in the control group(4.2 months),there was a statistically significant difference(χ^(2)=0.48,P=0.003);The median OS of patients in the test group(14.8 months)was not significantly different from that in the control group(13.2 months)(χ^(2)=0.15,P=0.704).After treatment,the expression level of serum VEGF-121[(201.25±18.37)ng/L vs.(276.83±20.26)ng/L],VEGF-145[(102.24±12.16)ng/L vs.(170.39±15.28)ng/L],VEGF-165[(135.08±14.32)ng/L vs.(210.53±16.09)ng/L]in the test group was lower than that in the control group,there were statistically significant differences(t=17.03,P<0.001;t=21.51,P<0.001;t=21.59,P<0.001).After treatment,patients in the test group were assessed according to 36-item Short-Form(SF-36)physiological function[(80.18±

关 键 词：乳腺肿瘤 治疗结果 药物相关性副作用和不良反应 贝伐珠单抗 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]